Neuraxpharm

Langenfeld, Germany Founded: 2009 • Age: 17 yrs Acquired By Permira
CNS drugs and treatments are developed and commercialized by Neuraxpharm.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Neuraxpharm

Neuraxpharm is a company based in Langenfeld (Germany) founded in 2009 was acquired by Permira in September 2020. Neuraxpharm has completed 5 acquisitions, including Brain Therapeutics, Easypharm and FARMAX. Neuraxpharm operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.

  • Headquarter Langenfeld, Germany
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Neuraxpharm Bohemia S.R.O.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Permira

    & 1 more

  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    Permira

    & 1 more

    (Sep 22, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Neuraxpharm

Headcount 500-1000
Employee Profiles 60
Employee Profiles
People
Gerard de Antonio Cot
Sales Area Manager At Neuraxpharm - Middle East & Africa
People
Vikas Mohan Sharma
Chief Medical Officer
People
Massimo Capella
Country Manager, Italy
People
Mercedes Prior
Head Of Corporate Market Access

Unlock access to complete

Funding Insights of Neuraxpharm

Premium access

Detailed funding history for Neuraxpharm

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Neuraxpharm

Neuraxpharm has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Permira and Apax Partners.

All
Venture Fund
Investor Description Founded Year Domain Location
Equity investments are focused on tech, services, and consumer sectors.
Locked Locked Locked
Investments are made in technology, consumer, healthcare, and service sectors.
Locked Locked Locked
Premium access

Investor details for Neuraxpharm

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Neuraxpharm

Neuraxpharm has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Brain Therapeutics, Easypharm and FARMAX.

Investments
Premium access

Investment portfolio details for Neuraxpharm

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Diversified pharmaceutical drugs are distributed across Brazil.
Locked Locked 2021 Locked
Seed oil and organic seed cannabis services are provided.
Locked Locked 2017 Locked
Neurological services are offered at a standalone clinic in Athens.
Locked Locked 2012 Locked
Premium access

Complete acquisition details for Neuraxpharm

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Neuraxpharm

Premium access

Detailed financials for Neuraxpharm

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Neuraxpharm Comparisons

Neuraxpharm Primary company
Description
CNS drugs and treatments are developed and commercialized by...
Location
Langenfeld, Germany
Founded Year
2009
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Neuraxpharm

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Neuraxpharm

Neuraxpharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Drugs for CNS disorders are developed and advanced.
Locked Locked Locked
Developer of therapeutic solutions for the treatment of diabetes
Locked Locked Locked
Genetically engineered cell therapies are developed for multiple disorders.
Locked Locked Locked
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Locked Locked Locked
Therapies for neurological and neuropsychiatric diseases are developed.
Premium access

Detailed competitors of Neuraxpharm

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Neuraxpharm

Premium access

Complete news archive for Neuraxpharm

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neuraxpharm

Neuraxpharm was founded in 2009.

Neuraxpharm is headquartered in Langenfeld, Germany. It is registered at Langenfeld, North Rhine-westphalia, Germany.

Jorg Thomas Dierks is the current CEO of Neuraxpharm.

Neuraxpharm was founded in 2009 and is headquartered in Langenfeld, Germany. Operations focus on the central nervous system sector, where established brands, value-added medicines, generics, consumer healthcare products, medical cannabis, digital health tools, medical devices, and orphan drugs are developed and commercialized. A broad portfolio of CNS treatment options is maintained to address patient needs across various conditions.

Neuraxpharm's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.

Neuraxpharm has made 5 acquisitions, including Brain Therapeutics, Easypharm, and FARMAX.

Neuraxpharm has 2 investors. Key investors include Permira, and Apax Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available